UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER
kmUU300MXic
kmUU300MXic
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Presentations<br />
Enabling a paradigm shift: A preference-tolerant RCT of personalized<br />
vs. annual screening for breast cancer.<br />
Authors*: Sarah Rosenberg-Wohl, Prihatha Narasimmaraj, Allison S Fiscalini, Karyn DiGiorgio, Lisa Latts,<br />
Marcus Thygeson, Martin Eklund, Jason Connor, Kristine Broglio, Jeffrey Tice, MaryBeth Kramer,<br />
Andrea LaCroix, Robert A. Hiatt, Barbara A. Parker, Tracy M. Layton, Laura Esserman<br />
Abstract #: e18281<br />
Presentation Date/Time: Publication Only<br />
Location: Publication Only<br />
Session: Publication Only<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr e18281)<br />
Esserman Research Interests: Dr. Esserman, surgeon & breast cancer oncology specialist, is the Carol Franc<br />
Buck Breast Care Center Director and co-leads the Breast Oncology Program. Her research is on improving<br />
healthcare value through integrating translational science, clinical informatics, systems re-engineering<br />
& clinical care delivery. In 2005, she received the NCI SPORE Investigator of the Year Award. In 2016 she<br />
received the Arbuckle Award from Stanford Graduate School of Business for Excellence in Management &<br />
was named to TIME’s 100 most influential people list. She is PI of the I-SPY TRIAL program, now a model for<br />
translational research & innovation in clinical trial design. She launched the Athena Breast Health Network to<br />
follow women from screening through treatment & outcomes, incorporating the latest in molecular testing &<br />
web-based tools. Athena just launched the WISDOM study to compare personalized vs annual breast cancer<br />
screening in 100,000 women and to predict who gets what kind of cancer.<br />
http://profiles.ucsf.edu/laura.esserman<br />
__________________________________________________________________________<br />
Non-invasive detection of crizotinib resistance in ALK-rearranged lung<br />
adenocarcinoma directs treatment with next-generation ALK inhibitors.<br />
Authors*: Nnamdi Ihuegbu, Kimberly C. Banks, Stephen R Fairclough, Oliver A. Zill, Darya Chudova,<br />
Richard Burnham Lanman, Collin M. Blakely<br />
Abstract #: e20643<br />
Presentation Date/Time: Publication Only<br />
Location: Publication Only<br />
Session: Publication Only<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr e20643)<br />
*<strong>UCSF</strong> authors in bold<br />
98
Change language